Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Ark Therapeutics
London, United Kingdomsmilestherapy.com ↗
- Ownership
- Private
- Employees
- ~100
- Development stage
- Preclinical
01
Overview
Ark Therapeutics Group was a UK-based biotech company focused on gene therapy. Its lead program, Cerepro, an adenoviral vector delivering thymidine kinase for malignant glioma, was submitted for EU approval but did not reach market. The company developed proprietary viral vectors for targeted delivery and also explored VEGF-gene therapies for cardiovascular indications. It eventually ceased operations and its assets were sold off.
- Therapeutic areas
- OncologyCardiovascularDermatologyHematology
- Modalities
- Gene therapyMedical device
- Industry
- Biotech
Beyond the preview
Go deeper on Ark Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ark Therapeutics.